Browse by category
Now showing items 61-80 of 197
-
Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: Systematic review and meta‐analysis including network meta‐analysis
(2020-10-31)Remdesivir is an antiviral agent that has shown broad‐spectrum activity, including against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clinical trials investigating the role of remdesivir in coronavirus ... -
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis
(2020-11-05)Objectives: Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our objective was to perform a living systematic ... -
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
(2020-07-03)Background: We conducted this systemic review and meta‐analysis in an attempt to evaluate the efficacy and safety of umifenovir in COVID‐19. Methods: We searched PubMed, Web of Science, Embase, Cochrane Library, CNKI and ... -
Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-Analysis
(2020-07-15)Background: The antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ) show promising SARS-CoV-2 anti-viral activity in vitro; however, clinical studies have reported conflicting results. We sought to systematically ... -
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study
(2020-07-08)Background: The outbreak of COVID-19 (caused by SARS-Cov-2) is very serious, and no effective antiviral treatment has yet been confirmed. The adage “old drug, new trick” in this context may suggest the important therapeutic ... -
Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review
(2020-10-29)Background: Coronavirus disease 2019 (COVID-19) is a newly discovered multi-organ disease caused by the novel coronavirus SARS-CoV-2. Currently, there are no official guidelines on the pharmacological treatment of COVID-19. ... -
Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study
(2020-05-08)While the recent study on the compassionate use of remdesivir for COVID-19 patients has shown a 68% clinical improvement7 it is a one-arm study that renders the evaluation of the efficacy in reducing death and the length ... -
Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers. A Living Rapid Review
(2020-05-05)Background: Health care workers (HCWs) are at risk for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Purpose: To examine the burden of SARS-CoV-2, SARS-CoV-1, and Middle Eastern respiratory syndrome ... -
Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials
(2020-11)Purpose: The present study systematically searched important medical databases, assessed the quality of available pieces of evidence, and performed a meta-analysis to test the efficacy of different therapeutic options ... -
Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis
(2020-06-25)Background: There is no vaccine or specific antiviral treatment for HCoVs infection. The use of type I interferons for coronavirus is still under great debate in clinical practice. Materials and methods: A literature search ... -
Exercise and acute respiratory infections: might regular exercise help protect us?
(2020-04-07)Among the rapid changes that coronavirus (Covid-19) has brought with it is a new enthusiasm for exercise. My husband, who has spent much of his career working on strategies to get the nation exercising, has looked on in ... -
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) has been reported in China since December 2019. More than 16% of patients developed ... -
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
(2020-03-18)An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) have been reported in China since December 2019. More than 16% of patients developed ... -
Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review
(2020-08)Despite high morbidity and mortality of ongoing coronavirus disease 2019 (COVID-19) pandemic, no specific therapy has been established till date. Though in vitro studies identified various molecules as possible therapies ... -
Extracorporeal Membrane Oxygenation in COVID-19 Treatment: a Systematic Literature Review
(2020-12-23)Introduction: The present study intends to systematically review the literature on the use of extracorporeal membrane oxygenation (ECMO) in patients with coronavirus disease 2019 (COVID-19). Methods: The research was carried ... -
Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup
(2020-09-22)Background: Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was ... -
Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Cohort Study
(2020-05-08)Background: The SARS-CoV-2 pandemic has resulted in enormous morbidity and mortality worldwide, yet no medications to date are proven to improve clinical outcomes in hospitalized COVID-19 patients. Famotidine is commonly ... -
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Importance: WHO has made the assessment that coronavirus disease 2019 (COVID-19) can be characterized as a pandemic. But there is no effective antiviral drug for COVID-19 so far. Objective: To compare the efficacy and ... -
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
(2020-09-24)Background: The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate, a purine nucleoside analog, inhibits that ... -
The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro
(2020-04-03)Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved ...